Abstracts tagged "Animal models and osteoarthritis"

Abstract Number: 2009 • 2015 ACR/ARHP Annual Meeting
CC-Chemokine Receptor 7 (CCR7) Deficiency Reduces Early Structural and Functional Features of Disease in a Murine Model of Osteoarthritis
Nisha Sambamurthy^1,2, Vu Nguyen^1,2, Patrick Diviney³, Justin Gan⁴, Charles Bush-Joseph⁵, Susanna Chubinskaya⁶, Anne-Marie Malfait⁷, George Dodge^2,3 and Carla R. Scanzello^8,9, ¹Medicine / Rheumatology, University of Pennsylvania, Philadelphia, PA, ²Research, Philadelphia VA Medical Center, Philadelphia, PA, ³Orthopedics, University of Pennsylvania, Philadelphia, PA, ⁴Rheumatology, Rush University Medical Center, Chicago, IL, ⁵Orthopedics, Rush University Medical Center, Chicago, IL, ⁶Biochemistry, Rush University Medical Center, Chicago, IL, ⁷Rush University Medeical Center, Chicago, IL, ⁸Rheumatology, University of Pennsylvania, Philadelphia, PA, ⁹Rheumatology, University of Pennsylvania Perelman School of Medicine & Philadelphia VA Medical Center, Philadelphia, PA
Background/Purpose: Synovial expression of CCR7 has been associated with inflammation and severity of symptoms in patients with meniscal tears and early osteoarthritis (OA). This receptor…
Abstract Number: 730 • 2012 ACR/ARHP Annual Meeting
Disease Modifying Effect of Strontium Ranelate in Experimental Dog Osteoarthritis: Inhibition of Major Catabolic Pathways
Jean-Pierre Pelletier¹, Mohit Kapoor², Daniel Lajeunesse², Hassan Fahmi³ and Johanne Martel-Pelletier¹, ¹Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ²Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, Canada, ³Pharmacology, Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada
Background/Purpose: To assess the disease modifying (DMOA) effect of strontium ranelate (SrRan) under therapeutic conditions on the progression of structural changes and on the major…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].